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Abstract
The BamHI A Rightward Transcripts are a set of alternatively splicing transcripts produced by
Epstein-Barr Virus that are highly expressed in nasopharyngeal carcinoma. These transcripts
contain several open reading frames as well as precursors for twenty two miRNAs. Although the
putative proteins corresponding to these open reading frames have not been detected, several
studies have identified properties that are interesting and potentially significant with respect to
cellular transformation. The miRNAs, however, are very abundant in all nasopharyngeal
carcinomas and several potentially significant functions have been identified for some of the
miRNAs. This article will focus on the nature of this complicated set of transcripts and the
evidence that they contribute to the development of nasopharyngeal carcinoma.
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1. Introduction
The Epstein-Barr Virus (EBV) is a ubiquitous member of the herpesvirus family that is
considered an etiologic factor in the development of several human malignancies. A major
malignancy is nasopharyngeal carcinoma (NPC) which occurs globally at a rate of 1 in
100,000 adults with highly elevated incidence of 20-50 per 100,000 in areas of southern
China. The first evidence of an association of EBV infection with NPC was the
identification of IgA antibodies to the EBV viral capsid antigen in NPC patient serum [1].
Subsequently EBV DNA was identified within the malignant epithelial cells of
undifferentiated NPC regardless of geographic location while in Southern China, EBV is
detected in all examples of NPC regardless of the differentiation subtype [2,3]. Furthermore,
a clonal EBV infection was found in early, preinvasive lesions suggesting a role in initiation
of NPC tumors [4]. The detection of the viral genome and viral proteins and RNAs in all
cells within a tumor strongly suggest a causative role for EBV infection in NPC.
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In NPC, EBV expression is restricted to a subset of the latent transcripts that are expressed
in EBV-transformed B-lymphocytes and in transplant-associated lymphoproliferative
disorders. Of the six EBV latent nuclear antigens, only EBNA1 expression is detected in
NPC tumor biopsies [5]. However, the latent membrane proteins LMP1 and LMP2A [5,6],
as well as two highly abundant, small noncoding RNAs (EBERs) [7], are consistently
expressed in NPC. In addition to these latent genes, BARF1, an early lytic protein in
infected lymphocytes, has been detected in NPC [8,9]. Importantly, the BamHI A rightward
transcripts (BARTs) are consistently and highly expressed in NPC [10]. The BARTs are an
overlapping group of differentially spliced RNAs that are 3’ coterminal and possibly initiate
from two transcriptional start sites [11]. The complex differential splicing produces multiple
open reading frames (ORFs) for proteins and precursors for microRNAs (miRNAs). The
potential contribution of the BARTs in the pathogenesis of NPC is likely to be continuingly
illuminating, however, this review will summarize our current understanding of the nature
and function of the BARTs with particular emphasis on relationships to NPC.
2. Identification and Structure of the BARTs
2.1. Initial Characterization and Expression Patterns of the BARTs
The BARTs were first identified as abundant viral transcripts in cDNA libraries prepared
from the C15 NPC tumor that is serially passaged in nude mice [12,13,14] Northern blotting
revealed a predominant band of 4.8kb that was expressed in this tumor, although several
other sized bands are also apparent [13,15]. Subsequent studies suggested that these
transcripts were present in other NPC xenografts as well as in NPC biopsies [10]. These
transcripts were striking in that they were highly abundant in NPC but had not been
identified in EBV transformed lymphocytes. However they were antisense to the several
known open reading frames encoding lytic proteins, including BALF5, the viral DNA
polymerase [14]. It was suggested that the transcripts may contribute to the inhibition of
replicative genes and were referred to as complementary strand transcripts (CSTs) [15].
Interestingly, this region was shown to be abundantly transcribed in early studies of viral
transcription in NPC and Burkitt's lymphomas (BL) biopsies [16,17]. Although BART
transcription can be detected using RT-PCR in all latently infected cell types, their relative
abundance is highest in the more restricted Type 1 and Type 2 patterns of latency found in
the tumors associated with EBV and low to undetectable in EBV transformed lymphocytes
expressing the Type 3 full pattern of latent genes [18,19]. Interestingly, most of the DNA
encoding the BART transcripts is deleted in the prototype B95-8 strain of EBV [20]. The
B95-8 cell line was selected for high virus production and the virus produced from it is
efficient in lymphocyte transformation. Additionally, a recombinant virus that is deleted for
the entire region of the genome encoding the BARTs is still capable of infecting and
transforming B lymphocytes in vitro [21]. These findings indicate that the BART transcripts
are not required for B-lymphocyte transformation which is in agreement with the negligible
levels of expression in Type 3 latency. However, the abundant expression of the BART
transcripts in EBV associated tumors that do not express most of the potent EBNA proteins
suggests that they are major contributors to tumor development or growth. It is also possible
that the BARTs contribute to the maintenance of latency through antisense effects on the
replicative genes on the opposite strand of the genome for the BARTs. Importantly, the
highest expression of the BARTs is detected in infected epithelial cells, including NPC and
gastric cancer, which may indicate that the BARTs have specific properties in epithelial
cells.
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2.2. Structure and splicing patterns of the BARTs
The BARTs are a series of transcripts that share a common 3’ terminus and are produced by
a complicated series of alternative splicing. A variety of experimental techniques including
sequencing DNA clones, RT-PCR, and RNase protection assays have been used to map the
various forms of the transcripts that exist in NPC, as well as other EBV-associated tumors
[11,22,23,24]. The general structure is one of seven exons (named I through VII), although
significant variety exists at multiple locations (Figure 1). Exons III, V, and VII contain
additional splicing sites that can result in excision of parts of those exons. Exons II and VI
are not always included in the final transcript and there are an additional two exons (Ia and
Ib) that are sometimes included between exons I and II.
There is no large ORF that spans the length of any of the identified BARTs, however, there
are several smaller ORFs that may encode for proteins. All of the transcripts contain exon
VII, which has a small ORF indicated by blue in Figure 1, that could potentially encode a
174 amino acid protein termed BamHI A rightward frame 0 (BARF0) [10]. This ORF is
particularly unusual in that the stop codon is embedded within a repeated polyadenylation
signal such that only a subset of the transcripts would encompass the stop codon. A subset of
these transcripts that contain alternative splicing in exon V and are directly spliced into the
BARF0 ORF in exon VII, which would produce a larger version of this protein (279 amino
acids) that has been referred to as RK-BARF0 [11]. An ORF, indicated in green, that spans
exons IV and V would encode for a 103 aa protein, which has been called RPMS1 or RK103
[24]. Perhaps most interestingly, a consistent splice pattern that spans exons V, VI, and a
distinct spliced form of exon VII results in an ORF indicated in yellow that is named A73 or
RB2, which would produce a 126 aa protein [23]. Evidence for and against the production of
the proteins from these ORFs will be reviewed in section 3.
2.3. The BART promoter and regulation of expression
Through sequencing of cDNA clones and 5’RACE the major transcriptional initiation site
(P1) for the BARTs has been mapped to nucleotide 138357 of the wild type EBV sequence
[11,24,25]. An alternative start site (P2) upstream from this has also been identified at
position 138067 [25]. These two transcriptional start sites appear to be under differential
regulation. The P1 site can be stimulated by binding of Jun family members to the consensus
AP-1 site directly upstream and can be suppressed by binding of IRF family members to an
IRF site [25]. The P2 site can be stimulated by c-myc and C/EBP family members and there
are potential myc and C/EBP binding sites directly upstream of P2 [25]. C/EBP family
members may be of significant interest since they are highly expressed in cells of epithelial
origin, thus, it has been hypothesized that upregulation of the transcription from the P2 site
may be responsible for the high levels of BARTs seen in NPC and other epithelial cells [25].
Many EBV latent promoters are regulated by methylation of CpG dinucleotides, with
decreased levels of methylation corresponding with increased levels of transcription [26]. In
NPC tumors and cell lines, the promoter region of the BARTs has been shown to be
hypomethylated compared to the rest of the genome, consistent with high levels of
expression [27,28]. Also, a recent report demonstrated that treatment of EBV-infected B
lymphocytes with a DNA methyltransferase inhibitor led to an induction of the BARTs,
consistent with a role of DNA methylation in regulating the BART promoter [29].
3. Potential BART-encoded proteins
Several open reading frames exist within the BARTs that have the potential to produce
proteins with interesting functions with respect to the development of NPC. However,
whether these proteins are actually translated in vivo remains a point of controversy.
Evidence for and against the relevance of these ORFs is presented below.
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3.1. BARF0 and RK-BARF0
All BARTs share the same 3’ end, and, therefore, share an ORF named BARF0, which is
located in the last exon of each transcript [10]. However, differential splicing can produce an
N-terminal extension of this ORF named RK-BARF0 [11]. In both of these ORFs, there is a
canonical poly-A addition sequence that occurs just upstream of the stop codon and 3’RACE
of these transcripts revealed that a majority terminate before the stop codon [11]. This calls
into question whether this ORF is actually translated to produce a protein in infected cells.
Currently, the experiments designed to determine whether the BARF0 or RK-BARF0 gene
products are actually made have been inconclusive. In vitro translated BARF0 could be
immunoprecipitated using serum from NPC patients suggesting these patients produced
antibodies directed against the protein [10]. In addition, cytotoxic T lymphocytes from
EBV-seropositive patients, but not –seronegative, exhibited a response when stimulated with
a BARF0 peptide [30]. However, a BL cell line expressing recombinant BARF0 did not
elicit a similar response [30]. A rabbit antibody generated to a peptide in BARF0 that bound
the exogenous BARF0 and RK-BARF0 on Western blots revealed evidence of 30 and 35 kD
proteins in many EBV-infected cell types [31]; however, these bands were also seen in some
EBV negative cell lines, suggesting a lack of specificity for this antibody [32] and
subsequent analysis revealed that this antibody also bound to HLA-DR β chain [33].
Affinity purification of this antibody removed this cross reactivity, but the affinity-purified
antibody could not consistently detect BARF0 protein in EBV-infected cells by Western
blotting [34].
Despite a lack of an ability to clearly demonstrate production of protein directly from the
BARTs, exogenous BARF0 and RK-BARF0 do have interesting biological properties.
Through both immunofluorescence of FLAG-tagged constructs and direct imaging of GFP-
tagged constructs, BARF0 and RK-BARF0 localized to the nucleus of transfected HeLa or
BL cell lines [32]. In addition, RK-BARF0 has been shown to interact with Notch family
members by yeast two-hybrid as well as immunoprecipitation [35]. Expression of RK-
BARF0 sequesters Notch in the nucleus, as well as promotes its proteasome-mediated
degradation, preventing its normal maturation and expression as a cell surface receptor and,
thus, also preventing its interaction with RBP-Jκ/CBF1 [34,35]. This is a potentially
interesting interaction given that the EBV latent protein EBNA2 requires binding RBP-Jκ to
activate transcription of genes such as the EBV oncoprotein LMP1 [36,37,38], and in fact,
expression of RK-BARF0 leads to an increased level of LMP1 [35].
3.2. RPMS1
The most proximal potential ORF in the BARTs spans the junction between exons IV and V
and would code for an 103 aa protein that has been termed RPMS1 (also known as RK103)
[11,24]. Given that the most abundant BARTs contain both RPMS1 and BARF0 on the
same transcript [23], a reasonable prediction would be translation of RPMS1 would be
favored as the proximal transcript on the message. However, detection of native RPMS1 has
also not been possible in EBV cell lines and tumors, despite the production of two
monoclonal antibodies that recognize the recombinant protein by immunofluorescence and
Western blotting [27].
However, similar to BARF0, RPMS1 also has interesting biological properties when
produced exogenously in cell lines. Overexpression of RPMS1 in HEK293 cells resulted in
increased growth in soft agar and cells that can form tumors in nude mice [39]. Flag-tagged
RPMS1 localized to the nucleus in both 293T and HeLa cells [23,40]. RPMS1 has been
shown through a variety of assays to bind to RBP-Jκ/CBF1 as well as with members of a
repressive histone deacetylase complex that interacts with RBP-Jκ [23,41]. This interaction
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has been shown to be able to inhibit RBP-Jκ-dependent Notch or EBNA2 gene activation
[23,41]. It is interesting that two potential proteins produced by the BARTs have the ability
to downregulate Notch signaling, suggesting that this pathway might be of particular interest
in EBV biology. Depending on context, Notch signaling can have both an oncogenic or
tumor suppressive phenotype [42], thus, it is not clear at this point how affecting this
pathway might contribute to NPC development.
3.3. A73
Alternative splicing within exon VII can produce an additional ORF that spans exons V, VI,
and VII that would code for a 126 aa protein that has been named A73, also known as RB2
[11,23]. As with the other potential BART proteins, monoclonal antibodies have been
unable to identify the native protein for this ORF in either EBV-infected cell lines or tumors
[27]. Unlike BARF0 and RPMS1, exogenously expressed A73 is a cytoplasmic protein. A
yeast two-hybrid screen identified interactions with both RACK1 (receptor for activated C
kinase 1) and β5-integrin [23]. RACK1 has been shown to regulate release of calcium ions
from intracellular stores and expression of A73 in 293 cells resulted in an increase of UTP
stimulated calcium release [27]. At this time it is unclear if this or another function of A73
might play a role in the development of NPC.
4. BART-encoded miRNAs
Perhaps the biggest finding with respect to the function of the BARTs was made when the
first viral miRNAs were cloned from an EBV-infected B cell line. Five miRNAs were
identified as being derived from the EBV genome, including two from the introns of the
BARTs [43]. Three of the miRNAs were located near the BHRF1 ORF that encodes a bcl2
homologue. These miRNAs have subsequently been shown to only be present in cells in
Type 3 latency that express the primary EBNA transcript that initiates from the Wp or Cp
promoters [44]. miRNAs are approximately 22 nucleotide RNAs processed from hairpin
structures of larger RNA that function in protein repression through a mechanism that is
similar to siRNAs [45]. As the putative protein products for the BART ORFs have not been
identified, the finding that the BARTs could serve as a template for miRNAs was a major
discovery. This initial study used cells infected with the B95-8 laboratory isolate, an unusual
strain of EBV that has a 12 kb deletion that spans many of the 5’ noncoding exons of the
BARTs [20]. Subsequent studies using cell lines infected with undeleted EBV as well as the
use of high throughput sequencing methods, have demonstrated that the BARTs encode for
22 miRNA precursors and because each miRNA hairpin can in principle code for two
miRNAs (one from each arm), as many as 44 mature BART miRNAs can be found in EBV-
infected cells[44,46,47,48].
4.1. BART miRNA nomenclature and expression patterns
The BART miRNAs have been named ebv-mir-BART1-22 with the numbers corresponding
to the order in which they were original discovered. In typical miRNA biogenesis, one
strand of the miRNA hairpin is selected to be the mature miRNA, while the other strand is
quickly degraded [45]. However, this is not always the case and in some instances, including
rather frequently for the BART miRNAs, both strands of the original hairpin persist and can,
therefore, be functionally relevant. To distinguish between the two potential miRNAs that
can be produced by each hairpin the suffixes -5p and -3p have been used to designate the 5’
end of the hairpin and 3’ end of the hairpin for cases in which there appears to be significant
mature miRNAs produced from each hairpin. In cases where one side of the hairpin is
dramatically favored over the other in terms of abundance, the less abundant miRNA is
designated with a *, consistent with the nomenclature used for all miRNAs, when referring
to the opposite, less abundant strand miRNA [45]. A complete listing of the EBV miRNAs
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with both mature and precursor sequences, as well as accepted nomenclature can be found at
www.mirbase.org.
A significant amount of effort has been made to determine the expression patterns of the
BART miRNAs. This is of interest primarily because the effectiveness of any particular
miRNA is necessarily tied to its abundance, as miRNA function is a process dependent upon
stoichiometric relationship of miRNA to target mRNA. While it is clear that in general the
BART miRNAs are expressed higher in cell lines and tumors in which the BARTs
themselves are expressed higher [44], it is also true that the concentrations of each of the
individual miRNAs vary by several orders of magnitude from each other.
Two methods have been used to determine the abundance of BART miRNAs in NPC tumors
and cell lines. The first is a step loop PCR method used to perform RT PCR from very small
RNA templates such as miRNAs [49]. This method has been used to profile the expression
levels of the BART miRNAs from both the NPC derived cell line, C666-1, as well as
directly from NPC biopsy samples [50,51,52,53]. In addition, relative abundance can be
determined by the relative representation in directly sequenced small RNA libraries; and
several groups have used both traditional and high throughput methods to sequence miRNAs
from NPC cell lines, xenografts, and biopsies [47,48,54]. Estimations can be made from
both of these methods with regards to copies of miRNA/cell; either from miRNA abundance
in a standard amount of total RNA in the case of PCR, or from the percentage abundance of
a particular miRNA with respect to the total pool in the case of sequencing. Both approaches
have determined that the individual BART miRNAs vary greatly in abundance in NPC, with
the most abundant being present at concentrations in the thousands of copies per cell and the
least abundant being expressed at a few copies per cell or less (Figure 2). Comparison of
these studies indicates that while some miRNAs appear to be consistently abundant in NPC
and others are hardly expressed at all, there is a significant percentage of the BART
miRNAs that vary greatly across studies. This variation appears to be due to more than just
differences in the samples used, as the profile of the relative abundance of miRNAs present
in the C666-1 cell line varies considerably. For example, the relative abundance of miR-
BART15 as determined by PCR differs considerably among three studies and is different if
determined by sequencing [50,51,54]. Strikingly one of the highest expressing miRNAs in
C666 cells by sequencing, miR-BART10 [54], only showed modest expression in the same
cells by RT-PCR [51]; whereas miR-BART19-3p, which appeared to be highly abundant in
PCR studies of cells or tumors [51,53], only appeared at low levels or was not detected at all
in sequencing studies [47,48,54]. In some instances, different studies yield opposite results
with respect to which strand of a miRNA is the dominant form. For example, in the two
PCR studies that have examined both miR-BART2-5p and -3p, one found the -5p version to
be several order of magnitude higher in abundance while the other study found the opposite
[51,53]; despite this neither appears in very high abundance in the sequencing studies
[47,48,54]. It is true that each method of estimating miRNA abundance comes with its own
caveats. The step loop PCR method relies on precise knowledge to the 3’ end of the miRNA,
which in the case of the BARTs has been shown to be variable throughout the population
[48]. Additionally, sequence-specific biases are also introduced by the RNA ligation step
used to generate small RNA libraries for sequencing [55].
The reason for the apparent differences in abundance of the individual BART miRNA
within a single infected cell is not known. Theoretically, such differences in steady state
levels could be due to differences in stability, differences in precursor transcription, or
differences in the processing to produce the mature miRNA. Relative stability of the various
BART miRNAs has not been evaluated to this date, so the extent to which that plays a role
in steady state abundance is not clear. It would seem unlikely that differential rates of
transcription could account for the different relative abundances as the miRNAs are tightly
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clustered in the BART introns, and should in theory all be transcribed together. The
differential splicing that occurs in the transcripts could possibly account for some of the
differences if specific splicing events favor or inhibit the excision of the miRNA hairpins
based on their location. In support of this possibility cell lines that accumulate higher levels
of the BART miRNAs also favor a version of the BART mRNA in which exon I is spliced
directly to exon III [22]. This is true despite the fact that the miRNAs appear to be processed
out of the initial transcript prior to completion of the splicing reaction, as stable RNAs
resulting from miRNA excision span the exon/intron boundaries [22]. It is presently
unknown whether the final spliced mRNAs are a product of splicing that occurs after the
excision of the miRNAs or they are made from a pool of transcripts that are distinct from
those that are the template for miRNA production. Further experimentation into the role
splicing plays in the production of the miRNAs will be necessary to clarify this issue.
Another possibility to explain the different levels of the BART miRNAs would be if each
miRNA is recognized with a different affinity for the enzyme responsible for the excision of
the hairpin, the Drosha/DGCR8 microprocessor complex [56]. This is another hypothesis
that has not been fully explored, but it is worth noting that the stable BART RNA fragments
that can be isolated from nuclei of EBV infected cell lines often have particular miRNAs
excised, while others have not been processed out, suggesting there is some order or bias to
the processing by the microprocessor complex [22].
4.2. Viral targets for BART miRNAs
In order to fully understand the potential role for the BART miRNAs in the development of
NPC, it is necessary to determine the targets of the miRNA-mediated downregulation. In
principle the targets could be other viral transcripts or transcripts from the host cell.
Targeting viral transcripts may be an important way to maintain latency by targeting of lytic
transcripts or to avoid immune detection through maintaining low levels of other latent gene
products. Perhaps the most straightforward function for a BART miRNA is in the case of
miR-BART2. miR-BART2 is located apart from the two clusters of miRNAs further
upstream and is directly antisense to the 3’UTR of BALF5, the viral DNA polymerase [43].
Given the obvious perfect complementarity of miR-BART2 to the BALF5 transcript, it is
not surprising that expression of the miRNA was shown to downregulate BALF5 protein
expression, through a mechanism that involves cleavage of the BALF5 mRNA at the site of
miR-BART2 binding [57]. There is also evidence that other BART miRNAs can regulate
the latent transcripts of EBV that are expressed in NPC. Several BART miRNAs from
cluster I have been shown to be able to target the 3’UTR of LMP1 and result in
downregulation of the protein [58]. In addition, a cluster II miRNA, miR-BART22, has been
shown to downregulate LMP2 at the protein level [54]. In all of these cases, the
consequences of miRNA action for the viral life cycle or for cancer progression have not
been fully explored. It will be interesting to determine whether any of these potential
functions for BART miRNAs contribute to EBV oncogenesis in vivo.
4.3. Cellular targets for BART miRNAs
For a majority of the BART miRNAs, a clear viral transcript target is not apparent. The most
likely function of these miRNAs would be downregulating transcripts from the host cell. In
the past few years, some progress has been made in identifying such targets. Excitingly,
many of the targets identified at this point have roles as tumor suppressors, further
highlighting the potential important role the BART miRNAs may play in the development of
NPC.
Several of the cellular targets identified to this date have roles in promoting apoptosis and,
thus, the miRNAs that target them have anti-apoptotic affects. miR-BART5 was predicted to
target the BH3-only protein PUMA, which helps mediate cytochrome c release from the
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mitochondria in response to apoptotic stimuli, through complementarity with the 3’UTR of
the PUMA mRNA [59]. Downregulation of PUMA by miR-BART5 was confirmed using
3’UTR reporter assays as well as Western blots . Another BH3-only protein, Bim, was
identified by microarray analysis looking for transcripts that decreased in abundance in cells
expressing the BART miRNAs [60]. Bim was also been shown to be targeted by multiple
BART miRNAs from cluster I through reporter assays and Western blots. Interestingly, Bim
is a tumor suppressor that is targeted by a number of oncogenic cellular miRNAs in other
forms of cancer [61,62,63]. In addition, in a study looking for EBV miRNA targets by
immunoprecipitating the RNA-induced silencing complex (RISC), TOMM22 was identified
as a potential target for miR-BART16 [64]. TOMM22 is a part of a mitochondrial pore
complex that serves as a receptor for the proapoptotic protein Bax; knockdown of TOMM22
by siRNA has been shown to be anti-apoptotic [65]. Targeting of TOMM22 was confirmed
by the 3’UTR reporter assay, although direct regulation of protein levels was not assessed
[64].
In addition to genes involved in apoptosis, other tumor suppressor genes have also been
implicated as targets for the BART miRNAs. Multiple tumor suppressors that target the Wnt
signaling pathway were shown to be downregulated by Western blots in cells expressing the
appropriate miRNAs, including WIF1 (miR-BART19-3p) and APC (miR-BART7, 19-3p,
and 17-5p) [53]. Other targets for BART miRNAs have also been identified in which the
role in NPC would be less clear including IPO7 for miR-BART3 [64], Dicer for miR-
BART6-5p [66], and MICB for miR-BART2-5p [67]. As each individual miRNA could
target multiple genes and pathways at the same time, it is likely that many more cellular
targets will be affected by the BART miRNAs.
4.4. BART miRNAs in the serum
In addition to being functionally relevant in the tumor cells they are produced in, tumor-
associated miRNAs can also be secreted from cells and are present in high copies in the
serum [68,69,70]. This is also true of the BART miRNAs, which are present in high
concentrations in the serum of NPC patients [53,71]. It is possible that the detection of
BART miRNAs in the serum of NPC patients might be used as a biomarker as tumor
specific cellular RNAs have proven to be useful in other types of cancer [72]. Given that
miRNAs in the serum are in a cell-free compartment that is highly stable and resistant to
RNAse [70], and the fact that miRNAs have been shown to be secreted from cells in small
vesicles known as exosomes [73], the current hypothesis is that most if not all of serum
miRNAs are contained within exosomes. The BART miRNAs have been shown to be
packaged into exosomes from both NPC xenografts and cell lines[71,74]. Interestingly, the
BART miRNAs can be transferred to recipient uninfected cells, and the transferred miRNAs
remain functional in downregulating protein expression [74,75]. This opens up the
possibility that the BART miRNAs may affect not only the EBV-infected cells of a tumor,
but the surrounding uninfected cells as well.
5. Conclusions and Future Directions
The EBV BARTs are a highly expressed and complicated set of transcripts that encode for a
large number of miRNAs, as well as potentially interesting proteins in NPC. Considering the
high levels of BART miRNAs that are detected in clinical samples and the lack of evidence
of BART protein production, it seems likely that the major role for these transcripts is the
production of miRNAs. It is not clear, however, if there is a situation in which the ORFs are
also translated. It is presently unknown whether one transcript can be processed for miRNA
production and also translated. A study of the BHRF1 miRNA production and effects on
BHRF1 mRNA and protein synthesis indicated that Drosha inhibition did not affect the
abundance or stability of the unspliced BHRF1 mRNA and suggested that the mRNAs might
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be produced from a distinct template [76]. It would be interesting to know if inhibiting
miRNA production by knocking down Drosha for example would enable translation of the
downstream ORFs. There appears to be a correlation between different splicing patterns and
the amount of miRNAs produced, which leads to the interesting hypothesis that production
of the miRNAs may influence the structure of the transcripts themselves and perhaps then
even the translation of potential ORFs. It could also be that forcing different splicing
patterns would result in a different balance of miRNAs/proteins produced as end products. A
better understanding of the mechanisms regulating the maturation of the BARTs might
identify factors that favor protein production over miRNA generation.
Many of the potential cellular gene products targeted by the BART miRNAs have important
functions and several possibly modulate apoptosis. The determination of whether the BART
miRNAs are necessary or sufficient for the growth properties characteristic of NPC will be
difficult. In addition to the difficulty in transforming epithelial cells by EBV infection, the
large number of BART miRNAs suggests the possibility that they may work in concert.
Thus, standard antisense inhibition experiments to determine if they are required for growth
or maintenance of tumors will be daunting. The identification of the expression patterns and
the functional capabilities of each individual miRNA will help in selecting candidate
miRNAs that possibly function as oncomirs. Despite the considerable effort in profiling
BART miRNA abundance, there are still large disparities in the various data sets. While
some of these disparities may be due to various biases in the techniques used, it is probably
also true that there are more complexities that have yet to be considered. For example, the
stability of each miRNA is completely unknown at this point, as is what factors might affect
that stability.
Considering the highly restricted patterns of viral protein expression in most of the tumors
associated with EBV, the abundance of the BART miRNAs suggests that they are likely to
be a major factor in the contribution of EBV to oncogenesis and in particular to NPC.
Although the overall biologic effects of these miRNAs are presently unknown, it is likely
that BART miRNA directed therapies will be developed as their molecular properties are
experimentally defined and their potential contribution to the pathogenesis of NPC is
clarified.
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Figure 1. Diagram of the BART transcripts
A diagram of the 22 kD BART locus drawn to scale. The exons are indicated as boxes and
are labeled with Roman numerals. The introns are indicated as lines between the boxes. The
positions of the potential open reading frames are indicated by color boxes. BARF0 is
shaded in blue, with the RK-BARF0 extension indicated by stripes. RPMS1 is indicated by
the green box and A73 with yellow. The position of the BART miRNAs are indicated by red
lines, and each are numbered according to the accepted nomenclature. The diagonal lines
below the transcript indicate the various splicing events that have been observed.
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Figure 2. Expression of the BART miRNAs from RT-PCR and small RNA sequencing studies in
NPC
A table comparing the available expression data for the BART miRNAs in NPC tumors and
the NPC cell line, C666. For each study, the expression levels of each miRNA were broken
into four categories, high (green), moderate (yellow), low (blue), or very low (purple). The
white boxes on the PCR half of the table indicate a miRNA that wasn't evaluated in that
study. The median values of each category differ by an order of magnitude. For the PCR
studies the green miRNAs indicate those expressed at approximately 10,000 copies/10μg
RNA, yellow ~1,000 copies, blue ~100 copies, and purple ~10 copies. For the sequencing
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studies, green indicates miRNAs that appear at a frequency of approximately 10% of the
total pool of miRNAs, yellow ~1%, blue ~0.1%, and purple ~0.01% to undetected.
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